Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 20/20 | 0.65 |
| ▸ | CDK2 | P24941 | 20/20 | 0.65 |
| ▸ | CCND1 | P24385 | 16/20 | 0.65 |
| ▸ | CDK6 | Q00534 | 16/20 | 0.65 |
| ▸ | CDK4 | P11802 | 4/20 | 0.65 |
| ▸ | CCND3 | P30281 | 1/20 | 0.65 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.48 |
| ▸ | CDK9 | P50750 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19863588 | 1.00 | CCNE1 (0.65) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL29640940 | 0.87 | CCND1 (0.60) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19857389 | 0.87 | CCND1 (0.60) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL29507679 | 0.81 | CDK2 (0.48) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL31153373 | 0.81 | CDK2 (0.58) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19857375 | 0.81 | CDK2 (0.58) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL22860376 | 0.79 | CCNE1 (0.44) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL26758841 | 0.79 | CCNE1 (0.61) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL29799023 | 0.79 | CDK2 (0.56) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL31153367 | 0.79 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114394966-B | Pyridopyrimidinone CDK2/4/6 inhibitors | 辉瑞公司 | 2024-10-11 | — | — | CN | disclosed |
| US-20220324872-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-11396512-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2022-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324872-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
| US-11396512-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.